Cellectar Biosciences (CLRB) Stock Price, News & Analysis

Company Overview

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Key Stats

• Today's Range: $4.72 to $5.30
• 50-Day Range: $4.34 to $10.97
• 52-Week Range: $4.11 to $68.70
• Volume: 321,754 shs
• Average Volume: 143,738 shs
• Market Capitalization: $15.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $375.00
• Consensus Rating: Moderate Buy

Cellectar Biosciences Stock Analysis - MarketRank™

Cellectar Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 591st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.59) to ($0.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectar Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectar Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectar Biosciences has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.56% of the float of Cellectar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cellectar Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectar Biosciences has recently increased by 115.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectar Biosciences does not currently pay a dividend.

Dividend Growth

Cellectar Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.56% of the float of Cellectar Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cellectar Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectar Biosciences has recently increased by 115.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.61

News Sentiment

Cellectar Biosciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cellectar Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Cellectar Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $124,750.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.04% of the stock of Cellectar Biosciences is held by insiders.

Percentage Held by Institutions

Only 16.41% of the stock of Cellectar Biosciences is held by institutions.

CLRB Stock Analysis - Frequently Asked Questions

How have CLRB shares performed this year?

Cellectar Biosciences' stock was trading at $8.97 on January 1st, 2025. Since then, CLRB stock has decreased by 46.3% and is now trading at $4.82.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) announced its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($3.39) earnings per share for the quarter, topping analysts' consensus estimates of ($3.60) by $0.21.
Read the conference call transcript.

When did Cellectar Biosciences' stock split?

Shares of Cellectar Biosciences reverse split on the morning of Friday, July 22nd 2022.The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Cellectar Biosciences' major shareholders?

Top institutional investors of Cellectar Biosciences include Geode Capital Management LLC (0.80%) and Riverview Capital Advisers LLC (0.58%). Insiders that own company stock include Jarrod Longcor, James V Caruso and Chad J Kolean.
View institutional ownership trends.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), HudBay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLRB
• CIK: 1279704
• Web: www.cellectar.com
• Phone: (608) 441-8120
• Fax: 608-441-8121
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cellectar Biosciences: $375.00
• High Price Target: $390.00
• Low Price Target: $360.00
• Potential Upside/Downside: +7,680.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($19.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -486.67%
• Return on Assets: -150.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 2.77

Miscellaneous

• Outstanding Shares: 3,190,000
• Free Float: 3,031,000
• Market Cap: $15.38 million
• Optionable: Optionable
• Beta: 0.42